CERC-301

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameCERC-301
Drug Alias NameRislenemdazCERC-301MK-0657
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor subunit epsilon 2 antagonists
TargetsGlutamate [NMDA] receptor subunit epsilon 2
Therapy Area/IndicationsDepressive Disorder, MajorParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCerecorAlto Neuroscience IncAvalo Therapeutics Inc +[5] 
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, MajorParkinson Disease

Other Information

ATC CodeN/A
Related LinksWikipedia